Vision Mission & Strength
R & D
Niprolac Oral Sol
Starcal D Forte
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Metavas MR (Trimetazidine Dihydrochloride) is the first 3- keto acyl CoA thiolase
inhibitor (KAT), a metabolic anti-ischemic agent with proven benefits for all coronary
patients. Metavas MR (Trimetazidine) inhibits fatty acid pathway by inhibiting 3-keto
acyl CoA thiolase enzyme and transfers oxygen to glucose pathway. Since glucose
pathway is more efficient in producing energy, the same oxygen produces more energy
and makes the heat more active. Moreover, the aerobic oxidation of glucose stops
production of lactic acid, which prevents angina pectoris.